Clinical trials
Meningococcal Vaccines clinical trials
Below are recruiting meningococcal vaccines clinical trials, each written for real people, not researchers. We’re tracking 17 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07505836RecruitingPhase 3
Meningitis vaccine trial for toddlers aged 12–23 months
This study tests a vaccine that protects against four common types of meningitis (groups A, C, Y, and W135) in toddlers aged 12–23 months. It helps researchers see if the vaccine is safe and works well for young children.
Nanning, GuangxiAges 1 year–1.9 years - NCT07505810RecruitingPhase 3
Meningitis vaccine trial for infants 3-5 months old
This trial tests a vaccine that protects against four types of meningococcal bacteria (groups A, C, W, and Y) in healthy babies aged 3 to 5 months. The vaccine is given to help prevent meningitis and other serious infections.
Nanning, GuangxiAges 3 months–5 months - NCT07505823RecruitingPhase 3
Meningococcal vaccine trial for infants 6-11 months old
This study tests whether a new vaccine safely protects infants aged 6 to 11 months against four types of meningococcal bacteria that can cause serious infections like meningitis and blood infections. It is designed for healthy babies who have not yet received any meningococcal vaccine.
Nanning, GuangxiAges 6 months–11 months - NCT04664569Recruiting
Study of treatments for bacterial meningitis in children
This study enrolls children and newborns with suspected or confirmed bacterial meningitis. The goal is to understand and improve care for serious infections that affect the lining around the brain.
CréteilAges 1 day–18 years - NCT06879327RecruitingPhase 2
Testing different schedules for an infant malaria vaccine
This trial is testing whether giving the R21 malaria vaccine to infants at different ages (starting at 2 months or 3 months) works as well as starting at 6 weeks. It will help find the best schedule to protect babies against malaria.
Bobo-DioulassoAges 1 month–2 months - NCT06834100RecruitingPhase 3
Comparing a new meningitis vaccine to an approved one
This trial tests a new meningitis vaccine (GNG-DE) to see how well it works compared to a vaccine already on the market. It might help protect you or your child from meningococcal disease.
KirovAges 3–55 - NCT07203755RecruitingPhase 1
Combination vaccine for whooping cough, Hib, and meningitis
This trial tests a new combination vaccine that protects against whooping cough, Haemophilus influenzae type b (a cause of meningitis and pneumonia), and several types of meningococcal disease (a cause of meningitis and bloodstream infections). It may help reduce the number of shots needed for children.
Shangqiu, HenanAges 2 months–6 years - NCT07204457RecruitingPhase 2/Phase 3
Meningococcal vaccine trial for healthy adults 19 to 55 years old
This trial tests a new meningococcal conjugate vaccine (EG-MCV4) in healthy adults to see how well the body's immune system responds and if it's safe. If you qualify, you'd help researchers learn if this vaccine can prevent meningococcal disease.
SeoulAges 19–55 - NCT07395739RecruitingPhase 1
Safety and immune response test of a new meningitis B vaccine
This trial tests a new vaccine called DX-104 to see if it is safe and helps the body fight meningitis B. Healthy adults aged 18-50 can join to help find a better way to prevent this infection.
Perth, Western AustraliaAges 18–50 - NCT04166656RecruitingPhase 3
Meningococcal B vaccine testing for people without a spleen
This Phase 3 trial tests how safe and how well the immune system responds to three different meningococcal B vaccine approaches in people who do not have a spleen. It may help future adults like you choose a safer, more effective prevention strategy against meningococcal B infection.
ParisAges 18–75 - NCT06025487RecruitingPhase 2
Meningococcal B vaccine study for asplenia
This study tests a meningococcal B vaccine in adults who have had their spleen removed or have a spleen that doesn't work well (asplenia). It will compare how well the vaccine works in these patients versus healthy adults to see if it provides good protection.
Vienna, State of ViennaAges 18–60 - NCT07379151Recruiting
Long-term protection from a meningococcal vaccine
This study checks whether the MenFive™ vaccine still protects against meningococcal disease more than five years after vaccination. It aims to see how long the immune response lasts.
BamakoAges 7–36 - NCT06832514RecruitingPhase 4
Gender and immune response to meningitis B vaccine
This study tests how well the meningitis B vaccine works in transgender and cisgender people. It aims to understand if sex and gender affect immune responses.
GhentAges 18–50 - NCT07621653Recruiting
Safety check-in after meningococcal vaccine in Korea
This study watches for any side effects or health changes after you receive the MenQuadfi vaccine, which protects against four types of meningococcal bacteria. Your doctor will follow up with you to make sure the vaccine is safe and working well.
BusanAges 1 month–55 years - NCT04875819RecruitingPhase 4
HIV vaccine safety check for meningitis and pneumonia shots
This trial studies how safe and how well the body’s immune system responds to meningococcal and pneumococcal vaccines in adults living with HIV. It may help confirm these vaccines work properly and are safe for people on HIV treatment.
HvidovreAges 18 years+ - NCT04843111Recruiting
Registry study for pregnancy exposure to MenQuadfi vaccine
This is an observational registry that collects information about pregnant people and their babies when MenQuadfi® (a meningitis vaccine) was given during pregnancy or shortly before pregnancy. It helps researchers understand what happens to women and offspring after this vaccine exposure.
Swiftwater, PennsylvaniaAges Any age - NCT07252804RecruitingPhase 4
Testing the MenB vaccine safety and immune response in children with rheumatic disease
This trial tests a meningitis B vaccine (MenB-4C) in children and young adults with autoimmune rheumatic diseases. It aims to see if the vaccine is safe and works well for these patients.
São Paulo, São PauloAges 2–25
Hear when a new Meningococcal Vaccines trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for meningococcal vaccines?
- Yes. Clin2 currently lists 17 recruiting meningococcal vaccines studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a meningococcal vaccines trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a meningococcal vaccines trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.